Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2010
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Centocor
- 08 Apr 2010 New trial record